Researcher:
Çelik, Yeliz

Profile Picture
ORCID

Job Title

Researcher

First Name

Yeliz

Last Name

Çelik

Name

Name Variants

Çelik, Yeliz

Email Address

Birth Date

Filters

2019 - 201912020 - 202316

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.1ced7489-d0b1-400b-9e52-442e0e21e4d6

Search Results

Now showing 1 - 10 of 17
  • Placeholder
    PublicationMetadata only
    Determinants of age-adjusted higher nt-pro-bnp values in adults with coronary artery disease and obstructive sleep apnea in the RICCADSA cohort
    (Elsevier, 2019) Glantz, H.; Thunstrom, E.; N/A; Peker, Yüksel; Aslan, Gamze; Çelik, Yeliz; Ural, Dilek; Faculty Member; Doctor; Researcher; Faculty Member; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); School of Medicine; N/A; N/A; School of Medicine; N/A; N/A; Koç University Hospital; N/A; 234103; N/A; N/A; 1057
    N/A
  • Placeholder
    PublicationMetadata only
    Effect of CPAP treatment on adhesion molecules in coronary artery disease with nonsleepy obstructive sleep apnoea: The RICCADSA randomized controlled trial
    (2020) Zou, Ding; Lindberg, Tülay; Thunstrom, Erik; N/A; N/A; Çelik, Yeliz; Peker, Yüksel; Researcher; Faculty Member; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); N/A; School of Medicine; N/A; 234103
    Background: Enhanced levels of vascular adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) have been associated with obstructive sleep apnoea (OSA). Impact of continuous positive airway pressure (CPAP) treatment on VCAM-1 and ICAM-1 levels in coronary artery disease (CAD) patients with OSA is unclear. Aims and Objectives: We aimed to evaluate whether CPAP therapy would reduce VCAM-1 and ICAM-1 after one year in a revascularized CAD cohort. Methods: This was one of the secondary outcomes of the RICCADSA trial, conducted in Sweden between 2005 and 2013. In all, 210 adults with nonsleepy OSA (apnea-hypopnea index ≥15/h, and Epworth Sleepiness Scale <10) were included. Participants were randomized to CPAP (n=104), or no-CPAP (n=106). Circulating levels of the adhesion molecules were assessed at baseline and after one year. Results: Median VCAM-1 decreased from 1055 to 979 ng/ml (p=0.02) in CPAP group, and from 1062 to 1034 ng/ml (p=0.95) in no-CPAP group. Similarly, median ICAM-1 reduced from 152 to 115 ng/ml (p<0.001) in CPAP group, and from 146 to 127 ng/ml (p=0.001) in no-CPAP group. Change from baseline in median values did not differ significantly between the groups. In a multivariate linear backward regression model, CPAP use (hrs/night) was associated with the decline in VCAM-1 (β=0.16 [95% CI 5.10-88.14], p=0.028), and tended to be significant with the decrease in the ICAM-1 (p=0.08). Conclusions: There was a natural decrease in the VCAM-1 and ICAM-1 values after one year in this CAD cohort with OSA. The magnitude of the decline was associated with increasing CPAP usage.
  • Placeholder
    PublicationMetadata only
    Association of TNF-ALPHA (-308g/a) gene polymorphism with circulating TNF-ALPHA levels and excessive daytime sleepiness in adults with coronary artery disease and concomitant obstructive sleep apnea
    (Amer Thoracic Soc, 2021) Thelander, T.; Yucel-Lindberg, T.; Thunstrom, E.; Behboudi, A.; N/A; N/A; N/A; Peker, Yüksel; Yazıcı, Duygu; Çelik, Yeliz; Faculty Member; PhD Student; Researcher; N/A; N/A; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); School of Medicine; Graduate School of Health Sciences; N/A; 234103; N/A; N/A
  • Placeholder
    PublicationMetadata only
    CPAP treatment increases anxiety in coronary artery disease patients with nonsleepy obstructive sleep apnoea: the RICCADSA randomized controlled trial
    (2020) Thunstrom, Erik; Strollo, Patrick J.; Peker, Yüksel; N/A; Çelik, Yeliz; Researcher; N/A; N/A
    Background: Revascularization is related with increased anxiety in coronary artery disease (CAD). Impact of obstructive sleep apnoea (OSA) as well as treatment with continuous positive airway pressure (CPAP) on anxiety in cardiac cohorts is unknown. Aims and Objective: We explored the state of anxiety after CPAP therapy in CAD patients with nonsleepy OSA. Methods: This was one of the secondary outcomes of the RICCADSA randomized controlled trial, conducted in Sweden between 2005 and 2013. In all, 237 adults with nonsleepy OSA (apnea-hypopnea index ≥15/h, and Epworth Sleepiness Scale <10) who filled the Zung Self-rating Anxiety Scale (SAS) were included. Participants were assigned to CPAP (n=119), or no-CPAP (n=118). Between-group difference in absolute change on the SAS scores after 3- and 12 months of CPAP therapy was examined. Results: Intention-to-treat analysis showed no significant difference between the CPAP and no-CPAP groups. Notwithstanding, there was an increase in the median score (+3.75 points) after 3 months in the group using the device at least 3 hrs/night, while there was a decline (-1.25 points) in the non-adherent/no-CPAP group (p=0.01). The increase in the SAS score (+1.25 points) in the adherent group and the decline (-1.25 points) in the non-adherent/no-CPAP group remained significant after one year (p=0.04). In a multivariate linear regression model, there was an association between the increase in the SAS scores and CPAP hrs/night (β coefficient =0.14 [95% CI 0.00-0.69], p=0.05). Conclusions: CPAP treatment increases anxiety in revascularized CAD patients with nonsleepy OSA.
  • Placeholder
    PublicationMetadata only
    Cardiovascular outcomes in adults with coronary artery disease and obstructive sleep apnea with versus without excessive daytime sleepiness in the RICCADSA clinical trial
    (American Thoracic Society (ATS), 2023) Eulenburg Christine; Redline, Susan; Thunström, Erik; Glantz, Helena; J Strollo Jr, Patrick; N/A; N/A; Çelik, Yeliz; Peker, Yüksel; Researcher; Faculty Member; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); N/A; School of Medicine; N/A; 234103
    Rationale: recent randomized controlled trials did not show cardiovascular benefits of continuous positive airway pressure (CPAP) in adults with coronary artery disease (CAD) and obstructive sleep apnea (OSA) in intention-to-treat analyses. It has been argued that exclusion of patients with OSA with excessive daytime sleepiness (EDS), who may be most likely to benefit from CPAP treatment, may be a reason for the null results. Objectives: we addressed 1) the effect of concomitant EDS on adverse outcomes in patients with CAD and OSA; and 2) whether the cardiovascular benefit of CPAP adherence differs between individuals with versus without EDS. Methods: this was a secondary analysis of the RICCADSA (Randomized Intervention with CPAP in CAD and Obstructive Sleep Apnea) trial, conducted in Sweden between 2005 and 2013. Data were analyzed from 155 patients with CAD with OSA (apnea-hypopnea index ⩾ 15/h) and EDS (Epworth Sleepiness Scale score ⩾ 10), who were allocated to CPAP and 244 patients without EDS (ESS < 10), who were randomized to CPAP or no CPAP. Patients who were allocated to no CPAP or were nonadherent (CPAP usage < 4 h/night) were compared with adherent patients (CPAP usage ⩾ 4 h/night) at 1-year follow-up. Inverse probability of treatment weighting was applied to mimic randomization of EDS. The primary endpoint was the first event of repeat revascularization, myocardial infarction, stroke, or cardiovascular mortality. Results: the median follow-up was 52.2 months. The incidence of the primary endpoint did not differ significantly between the EDS versus no-EDS groups in the entire cohort. Within the adherent group, patients without EDS had a significantly decreased risk compared with patients with EDS (adjusted hazard ratio, 0.41; 95% confidence interval, 0.20-0.85; P = 0.02). Conclusions: adverse cardiovascular outcomes did not differ by degrees of EDS for patients with CAD with OSA who were untreated or nonadherent to treatment. CPAP use, at least 4 h/night, was associated with reduced adverse outcomes in participants without EDS.
  • Placeholder
    PublicationMetadata only
    Determinants of high circulating myeloperoxidase and matrix metalloproteinase-9 levels in coronary artery disease patients with obstructive sleep apnea: a secondary analysis of the RICCADSA study
    (Elsevier, 2022) N/A; N/A; Peker, Yüksel; Özkan, Esra; Çelik, Yeliz; Faculty Member; Researcher; Researcher; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); School of Medicine; Graduate School of Social Sciences and Humanities; Graduate School of Health Sciences; 11480; N/A; N/A
    N/A
  • Placeholder
    PublicationMetadata only
    Association of REM predominant obstructive sleep apnoea severity with depression and quality of life in adults with coronary artery disease in the RICCADSA cohort
    (European Respiratory Society (ERS), 2022) N/A; Balcan, Mehmet Baran; Çelik, Yeliz; Peker, Yüksel; Faculty Member; Researcher; Faculty Member; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); School of Medicine; N/A; School of Medicine; Koç University Hospital; N/A; N/A; 172783; N/A; 234103
    Background: Obstructive sleep apnoea (OSA) is common in adults with coronary artery disease (CAD). OSA that occurs predominantly during REM-sleep has been identified as a specific OSA phenotype. Aims and Objective: We addressed whether or not there is a dose-response relationship between REM-predominant OSA and functional outcomes, mood and quality of life in a CAD cohort. Methods: The current study was a secondary analysis of the RICCADSA trial. In all, 286 OSA patients with total sleep time ≥240 min, and REM sleep ≥30 min, were included. REM- predominant OSA was defined as REM-apnoea hypopnoea index (AHI) /non-REM (NREM)-AHI ≥2. Multiple regression analyzes were used to address the association of REM-AHI with the Functional Outcome of Sleep Questionnaire (FOSQ), Zung Self-rated Depression Scale (SDS) and Anxiety Scale (SAS) as well as Short Form-36 Health Survey (SF- 36) scores. Results: In all, 73 (25.5%) had REM-predominant OSA. There was a significant dose-response relationship between Zung SDS scores and REM-AHI. No correlation was found between REM-AHI and FOSQ as well as Zung SAS scores. SF-36 subdomains vitality, mental health, and mental composite score (MCS) were inversely correlated with REM-AHI. In the multivariate models, only the inverse relationship between REM-AHI and MCS remained significant after adjustment for age, body-mass-index, and sex (β-coefficient -2.20, %95 CI [-0.56, -0.03] ; p=0.03). Conclusions: Our results suggest an independent inverse dose-response relationship between REM-AHI and mental composite score. The relationship between REM-AHI and SDS, vitality and mental health were dependent on female sex.
  • Placeholder
    PublicationMetadata only
    Cardiovascular outcomes in patients with coronary artery disease and nonsleepy versus sleepy obstructive sleep apnoea phenotypes in the RICCADSA trial
    (European Respiratory Soc Journals Ltd, 2021) Eulenburg, Christine; Thunstrom, Erik; Çelik, Yeliz; Peker, Yüksel; Researcher; Faculty Member; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); N/A; N/A; School of Medicine; N/A; 234103
    Background: Recent data suggests that obstructive sleep apnoea (OSA) patients with sleepy phenotype have poorer prognosis compared to nonsleepy patients. Less is known regarding the interaction between sleepiness and adverse outcomes in cardiac patients. Aims: We investigated the incidence of major adverse cardiovascular and cerebrovascular events (MACCE) in coronary artery disease (CAD) patients with OSA. Methods: In a secondary analysis of the RICCADSA trial, data were analyzed from 399 patients (apnoea-hypopnoea index [AHI] ≥15/hr) with nonsleepy (Epworth Sleepiness Scale [ESS]<10) OSA, who were randomized to continuous positive airway pressure (CPAP) (n=122), or no-CPAP (n=122), and 155 sleepy (ESS≥10) patients, who were allocated to CPAP. Untreated/non-users, intermittent CPAP users, and frequent users were compared (0, 0.1-3.9, and ≥4 hours/day, respectively). Propensity scoring was applied to mimic randomization. The primary endpoint was the first event of MACCE. Median follow-up was 52.2 months. Results: The primary outcome did not differ between CAD patients with sleepy vs nonsleepy OSA among untreated/non-CPAP users and intermittent users. In the frequent user group, the sleepy phenotype had a significant risk increase (adjusted hazard ratio 3.08, 95% CI 1.20-7.89; p=0.019) compared with the nonsleepy patients. Conclusions: CAD patients with sleepy and nonsleepy OSA have a similar risk profile when they are untreated or less adherent to CPAP. At least 4 hours of CPAP usage reduces the risk in nonsleepy OSA. Patients with sleepy OSA may need to use the device longer in order to achieve cardiovascular benefits.
  • Placeholder
    PublicationMetadata only
    Postoperative Atrial Fibrillation in Adults with Obstructive Sleep Apnea Undergoing Coronary Artery Bypass Grafting in the RICCADSA Cohort
    (Elsevier, 2022) Hjalm, H. Holtstrand; Thunstrom, E.; N/A; Peker, Yüksel; Çelik, Yeliz; Faculty Member; Researcher; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); School of Medicine; N/A; 234103; N/A
    N/A
  • Thumbnail Image
    PublicationOpen Access
    REM-predominant obstructive sleep apnea in patients with coronary artery disease
    (Multidisciplinary Digital Publishing Institute (MDPI), 2022) Newitt, Jennifer; Strollo, Patrick J., Jr.; Balcan, Mehmet Baran; Çelik, Yeliz; Peker, Yüksel; Researcher; Faculty Member; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); School of Medicine; Koç University Hospital; N/A; N/A; 234103
    Obstructive sleep apnea (OSA) is common in adults with coronary artery disease (CAD). OSA that occurs predominantly during rapid-eye movement (REM) sleep has been identified as a specific phenotype (REM-predominant OSA) in sleep clinic cohorts. We aimed to examine the association of REM-predominant OSA with excessive sleepiness, functional outcomes, mood, and quality of life in a CAD cohort, of whom 286 OSA patients with total sleep time >= 240 min, and REM sleep >= 30 min, were included. REM-predominant OSA was defined as a REM-apnea-hypopnea-index (AHI) /non-REM (NREM) AHI >= 2. In all, 73 (25.5%) had REM-predominant OSA. They were more likely to be female (26.0% vs. 9.9%; p = 0.001), and more obese (42.5% vs. 24.4%; p = 0.003) but had less severe OSA in terms of AHI (median 22.6/h vs. 36.6/h; p < 0.001) compared to the patients with non-stage specific OSA. In adjusted logistic regression models, female sex (odds ratio [OR] 4.64, 95% confidence interval [CI] 1.85-11.64), body-mass-index (BMI; OR 1.17; 95% CI 1.07-1.28) and AHI (OR 0.93, 95% CI 0.91-0.95) were associated with REM-predominant OSA. In univariate linear regression models, there was a dose-response relationship between REM-AHI and Zung Self-rated Depression Scale but not excessive sleepiness, functional outcomes, and anxiety scores. Among the Short Form-36 subdomains, Vitality, Mental Health, and Mental Component Summary (MCS) scores were inversely correlated with REM-AHI. In multivariate linear models, only MCS remained significantly associated with REM-AHI after adjustment for age, BMI, and sex (beta-coefficient -2.20, %95 CI [-0.56, -0.03]; p = 0.028). To conclude, female sex and BMI were related to REM-predominant OSA in this revascularized cohort. MCS was inversely associated with REM-AHI in the multivariate model.